Episode 1 - The role of Anti-PLA2R and other biomarkers in the diagnosis of membranous nephropathy
Speaker: Laurence Beck, MD, PHD, Associate Professor of Nephrology, Boston University School of Medicine

Date: Feb. 17th  | Time: 11AM - 12:30PM EDT   
Duration: 1.5 hours  |   P.A.C.E. Credits: 1

Watch Episode 1 here


Episode 2 - The role of PLA2R testing in pre- and post-renal transplant monitoring in membranous nephropathy
Speaker:  Jean Francis MD, Medical Director of Kidney Transplantation, Boston University Medical Center (BUMC)

Date: March 24th  |   Time: 11AM - 12:30PM EDT   
Duration: 1.5 hours  |   P.A.C.E. Credits: 1


Episode 3 - Detection of PLA2R and Other Antigens in Renal Biopsies as a cause of Primary Membranous Nephropathy
Speaker: Bernard Collins, Technical Director, R&D Immunopathology Unit, Massachusetts General Hospital, Associate in Pathology Harvard Medical School

Date: April 21st  |  Time: 11AM - 12:30PM EDT   
Duration: 1.5 hours  |   P.A.C.E. Credits: 1



1. Seitz-Polski B, Lambeau G, Esnault V. Membranous nephropathy: Pathophysiology and natural history. Nephrol Ther. 2017;13 Suppl 1:S75-s81

2-4: KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1-s276.

Our Speaker

DATE: APRIL 21st, 2021    |   TIME: 11:00 AM EDT

Bernard Collins received his degree in Chemistry from the University of Florida in 1970. He has worked in the Department of Pathology at the Massachusetts General Hospital in Boston since 1974. Currently, he is the Technical Director for Research and Development of the Immunopathology Unit at Massachusetts General Hospital and is Associate in Pathology at Harvard Medical School.  He has co-authored more 100 publications on the importance of Immunofluorescence in the diagnosis in renal biopsies and renal disease. In addition to this with his colleagues he developed several diagnostic assays for the diagnoses in renal disease; including the first to report that C4d is a marker for antibody mediated rejection in allograft kidney and cardiac biopsies, specific assays for ANCA detection, and a Western Blot Assay for the detection of the anti-alpha 3 chain of Type IV Collagen in patients with Goodpasture Syndrome and anti-GBM Disease. Bernie with his colleague developed a Western Blot Assay for the detection of Anti-PLA2R antibodies in serum and then worked with EUROIMMUN so that MGH was the first Lab in the USA to offer their FDA approved assay for the detection of anti-PLA2R antibody in patients with Membranous Nephropathy. 

DATE: APRIL 21st, 2022    |   TIME: 11:00 AM EDT

EUROIMMUN US is an approved provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.

Follow EUROIMMUN US on these featured platforms and receive regular updates on EUROIMMUN US and our products

What is Membranous Nephropathy?

Membranous nephropathy (MN) is an autoimmune disorder characterized by the presence of specific autoantibodies. These autoantibodies are responsible for disrupting the integrity of kidney specific cells, causing MN to serve as a major cause of nephrotic syndrome in adults. While antibodies against the phospholipase A2 receptor (PLA2R) represent up to 80% cases of MN, recent studies have identified novel autoantibodies that exist in PLA2R-seronegative patients.

In this webinar, Bernard Collins will
discuss the available tests for detection of autoantibodies in MN and describe the strategy for the discovery of novel MN antigens in renal biopsies.

For More Information please visit pla2r.com


EUROIMMUN US · NJ 07046 · 800.913.2022 · scientificaffairs@euroimmun.us · www.euroimmun.us



  1.  Identify the autoantibodies associated with membranous nephropathy (MN)
  2. Discuss the tests used to detect autoantibodies in MN
  3. Describe innovations within current guidelines regarding testing, monitoring, and treatment of MN

Learning Objectives